NASDAQ: KRRO · Life Sciences · 5 alerts · CIK 1703647
Share price
$12.71Close, Nov 16
Market cap
$174M
Shares outstanding
13.73MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Korro Bio, Inc. filings on SEC EDGAR ↗
Korro Bio announced positive preclinical results for KRRO-111, its RNA-editing development candidate for Alpha-1 Antitrypsin Deficiency (AATD). The studies demonstrated up to 95% mRNA editing and a 6-fold increase in total functional AAT protein, supporting a potential best-in-class profile for treating both lung and liver manifestations of the disease.
Korro Bio announced the dosing of the first cohort of participants in its ANCHOR Phase 1/2 clinical trial for KRRO-121, an RNA-editing oligonucleotide targeting hyperammonemia in patients with urea cycle disorders (UCD). The trial is currently enrolling healthy volunteers in Australia for safety and PK evaluation, with dosing in UCD patients expected to begin in the first half of 2027.
“Dosing the first cohort in ANCHOR is a step towards gaining evidence on safety first and then activity. Providing the potential for peace of mind for patients with a UCD, irrespective of their mutational background, is something we hope to demonstrate through this trial.”
Ram Aiyar, PhD, Chief Executive Officer and President of Korro